| Hemolytic reactions to nitrofurantoin in patients with glucose-6-phosphate dehydrogenase deficiency: theory and practice. | |
| | |
MedLine Citation:
|
PMID: 2089833 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The prescribing information for nitrofurantoin states that patients with glucose-6-phosphate dehydrogenase deficiency may experience hemolysis following administration of the drug. Although there is no doubt that this statement is qualitatively correct, the degree of risk in the general population of patients has not been previously quantified. This study was designed to estimate the degree of risk of a clinically important hemolytic reaction to nitrofurantoin by means of a retrospective analysis of the Norwich Eaton adverse reaction database. Since 1953, approximately 130 million courses of nitrofurantoin therapy have been distributed in the U.S. alone. The database contained 127 reports of hemolytic reactions; a "worst-case" estimate of the incidence rate was 1 in 100,000 courses of therapy. Considering the extensive usage of nitrofurantoin, clinically important hemolytic reactions appeared to be very rare. For the cases in which outcome was recorded, complete recovery occurred in 87 percent of patients. Although nitrofurantoin is contraindicated after the onset of labor and in infants less than one month old, no well-documented cases of hemolytic reactions in neonates were identified. |
| | |
Authors:
|
J E Gait |
Related Documents
:
|
12410943 - Local anesthetic cartridges and latex allergy: a literature review. 7811183 - Ipsilateral post-cast hypertrichosis and dyshidrotic dermatitis. 21307683 - Amiodarone-induced hypothyroidism and other adverse effects. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: DICP : the annals of pharmacotherapy Volume: 24 ISSN: 1042-9611 ISO Abbreviation: DICP Publication Date: 1990 Dec |
Date Detail:
|
Created Date: 1991-05-30 Completed Date: 1991-05-30 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 8904338 Medline TA: DICP Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1210-3 Citation Subset: IM |
Affiliation:
|
Department of Medical Affairs, Norwich Eaton Pharmaceuticals, Inc., NY 13815. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia, Hemolytic
/
chemically induced*,
epidemiology Female Glucosephosphate Dehydrogenase Deficiency / blood, drug therapy* Hemolysis* Humans Infant, Newborn Nitrofurantoin / contraindications* Pregnancy Pregnancy Complications / epidemiology Retrospective Studies Risk Factors |
| Chemical | |
Reg. No./Substance:
|
67-20-9/Nitrofurantoin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oxygen homeostasis: theory, measurement, and therapeutic implications.
Next Document: A review of carbamazepine's hematologic reactions and monitoring recommendations.